Cardio-renal interaction - Clinical trials update 2022

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Chronic kidney disease (CKD) is a significant cardiovascular risk factor, increasing morbidity and mortality.
• The cardiorenal syndrome highlights the intricate pathophysiological link between the heart and kidneys.
• Understanding these interactions is crucial for managing complex patient populations.

Purpose of the Study:

• To review recent clinical studies (2021-2022) on cardiorenal interactions.
• To discuss novel therapeutic agents and their impact on cardio-renal health.
• To provide updated insights into managing cardiovascular and kidney diseases.

Main Methods:

• Literature search of high-impact journals via PubMed.
• Inclusion of clinically relevant trials published in 2021 and 2022.
• Critical review of studies on specific drugs and conditions.

Main Results:

• New evidence on finerenone (mineralocorticoid receptor antagonist) and SGLT2-Inhibitors for renoprotection.
• Updated insights into treating arterial hypertension in severe CKD with chlorthalidone.
• Review of data on infective endocarditis in hemodialysis patients and etelcalcetide for secondary hyperparathyroidism.

Conclusions:

• Recent studies on cardiorenal interactions offer significant findings that may influence clinical practice.
• The reviewed evidence provides a contemporary perspective on managing patients with combined cardiac and kidney conditions.
• Further research and clinical application of these findings are warranted.